Pharmaceuticals News

SEATTLE, April 15, 2026 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune...

CAMBRIDGE, Mass., April 15, 2026 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage biotechnology company focused on unlocking the broad potential of RNA medicines to...

Expanded treatment in community settings will reduce patient burdenOption to redose patients granted in both Ntrust-1 and Ntrust-2 studiesRheumatoid arthritis cohort to be added to Ntrust-2Dosing...

Arcutis today announced that it will report its Q1 2026 financial results and provide a business update on May 6, 2026 after the U.S. markets close.

Elion Therapeutics initiated a Phase 2 study of turletricin in invasive mould infection ("TREAT-1") and is presenting early clinical data at ESCMID 2026.

Ms. Deardorf is an experienced biopharma leader who will lead business development and corporate and commercial strategy as Neutrolis advances NTR-1011 into autoimmune diseases following positive...

Allschwil, 15. April 2026 Basilea Pharmaceutica AG, Allschwil (SIX: BSLN), ein biopharmazeutisches Unternehmen mit bereits vermarkteten Produkten und dem Ziel, Patienten zu helfen, die an schweren...

Allschwil, Switzerland, April 15, 2026 Basilea Pharmaceutica Ltd, Allschwil (SIX: BSLN), a commercial-stage biopharmaceutical company committed to meeting the needs of patients with severe bacterial...

Researchers at IOB developed targeted delivery of healthy mitochondria to diseased cells, opening new paths for treating mitochondrial disorders.

Ken Paxton’s Lululemon investigation (NASDAQ:LULU) is a wake-up call for the entire synthetic textile industry, as it’s time to move to better fibers like